AccuVein’s AV300 helps healthcare professionals locate veins for bloodstream pull, IV infusion and bloodstream donation by projecting a pattern of light on patient’s skin that reveals the positioning of underlying veins. Hospitals are adopting vein visualization as the standard-of-treatment for venipuncture as a tool to reduce error, reduce increase and cost patient satisfaction, said AccuVein engineering vice president Joe Zott. .. AccuVein receives QTDP grant for AV300 vein illumination system AccuVein LLC, the programmer of the first noncontact, handheld vein illumination program, announced today that it had been awarded the utmost grant amount from the Qualifying Therapeutic Discover Task program.Dr. Carl H. At the Abramson Cancer Center of the University of Pennsylvania and Dr June. Aaron Rapoport of the University of Maryland Greenebaum Malignancy Middle developed the scholarly study design, which was offered to the National Institutes of Health Recombinant DNA Advisory Committee this past year. Dr. June may be the regulatory sponsor for the analysis, and Dr. Edward Stadtmauer is the lead scientific investigator at the Abramson Malignancy Center. Dr. Rapoport may be the lead medical investigator at the University of Maryland. Adaptimmune Ltd is the financial sponsor and owns the core T cell receptor technology. Multiple myeloma can be a hematologic malignancy localized to the bone marrow.S. Rapoport, Stadtmauer and June have collaborated and extensively published on three prior medical trials evaluating T cell infusion post ASCT, and have demonstrated that the task is safe and promotes reconstitution of the disease fighting capability.